Bruker Corporation
BRKR
Κατάταξη σε μετοχές
#2312
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Τιμή μετοχής
$56.53
Τελευταίος συγχρονισμός: 2026-10-20
Κεφαλαιοποίηση
$8.61B
Αλλαγή (1 ημέρα)
2.09%
Αλλαγή (1 έτος)
45.77%
Χώρα
US
Εμπόριο Bruker Corporation (BRKR)
Κατηγορία
Healthcare
Έσοδα για την Bruker Corporation (BRKR)
Έσοδα τον Jun 2026 TTM: $3.50B
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Bruker Corporation, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $3.50B. Το 2024, η εταιρεία είχε έσοδα $3.37B αύξηση σε σχέση με τα έσοδα του έτους 2023, τα οποία ήταν $2.96B. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Bruker Corporation από 2000 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $3.50B | 1.84% |
| 2025 | $3.44B | 2.08% |
| 2024 | $3.37B | 13.56% |
| 2023 | $2.96B | 17.14% |
| 2022 | $2.53B | 4.67% |
| 2021 | $2.42B | 21.66% |
| 2020 | $1.99B | -4.11% |
| 2019 | $2.07B | 9.34% |
| 2018 | $1.90B | 7.34% |
| 2017 | $1.77B | 9.59% |
| 2016 | $1.61B | -0.77% |
| 2015 | $1.62B | -10.23% |
| 2014 | $1.81B | -1.66% |
| 2013 | $1.84B | 2.68% |
| 2012 | $1.79B | 8.46% |
| 2011 | $1.65B | 26.58% |
| 2010 | $1.30B | 17.08% |
| 2009 | $1.11B | 0.67% |
| 2008 | $1.11B | 102.18% |
| 2007 | $547.58M | 25.64% |
| 2006 | $435.83M | 46.46% |
| 2005 | $297.57M | 4.62% |
| 2004 | $284.42M | 9.11% |
| 2003 | $260.68M | 124.01% |
| 2002 | $116.37M | 25.54% |
| 2001 | $92.69M | 21.00% |
| 2000 | $76.60M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $46.59B | 1,231.15% |
US
|
|
| $35.48B | 913.94% |
IE
|
|
| $25.84B | 638.28% |
US
|
|
| $21.00B | 499.95% |
US
|
|
| - | - |
DE
|
